Despite MRM-MS's Promise as a Clinical Platform, Technical Hurdles and High Costs Remain Problematic

With diagnostic development shifting from single-marker to multi-marker tests, multiple-reaction monitoring mass spectrometry has emerged as a potentially valuable clinical tool. Further improvements in the platform's cost and variability are needed, however, to make it competitive with immunoassays.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.